Boehringer Ingelheim

This study tests whether adding an experimental drug called obrixtamig to standard chemotherapy and immunotherapy helps people with advanced small cell lung cancer live longer. About 670 adults with extensive-stage disease will be randomly assigned to receive either the new combi…

This early-phase study tests a new drug called BI 764532 added to standard chemotherapy for people with advanced neuroendocrine carcinoma (NEC). The goal is to find a safe dose and see if the combination helps shrink tumors. About 55 adults whose cancers have a specific marker (D…

This study tests whether adding vicadrostat to the standard drug empagliflozin helps people with heart failure who have a preserved ejection fraction (pumping ability of 40% or more). About 6,000 adults with symptoms will be randomly assigned to receive either the combination or …

This study tests if spesolimab can close painful skin ulcers in adults with pyoderma gangrenosum, a rare inflammatory condition. About 90 participants will receive either the drug or a placebo, along with oral steroids for the first 8 weeks. The main goal is complete ulcer healin…

This study tests whether adding BI 690517 to empagliflozin helps slow kidney disease in 11,000 adults with chronic kidney disease. Participants take the study drugs or placebos for about 3-4 years. Doctors track kidney function, heart failure hospitalizations, and heart-related d…

This study tests a weekly injection called survodutide in 1800 adults with NASH/MASH and moderate to advanced liver fibrosis. The goal is to see if the drug can reverse liver scarring or resolve the liver disease without making it worse. Participants receive either survodutide or…

This study tests an experimental tablet, BI 764198, in adults and teens with certain kidney diseases that cause protein to leak into urine. About 132 participants will be randomly assigned to take the drug or a placebo once daily for 20 weeks, while continuing their usual care. T…

This study tests a new medicine, BI 765423, for people with idiopathic pulmonary fibrosis (IPF), a disease that scars the lungs and makes breathing hard. About 71 adults aged 40 and older will receive either the drug or a placebo (fake drug) as an IV infusion every 4 weeks for 3 …

This study tests an oral medication called BI 764198 for people with a kidney disease called focal segmental glomerulosclerosis (FSGS). About 286 adults and teens will take either the study drug or a placebo once daily for up to 2 years, while continuing their usual FSGS treatmen…

This study tests a new tablet called nerandomilast for adults with lung scarring caused by autoimmune rheumatic diseases like rheumatoid arthritis or scleroderma. About 400 people who haven't improved on standard treatment will take either the drug or a placebo for at least 26 we…

This study tests whether adding a new medicine called vicadrostat to the standard drug empagliflozin can lower the risk of heart problems in adults with type 2 diabetes, high blood pressure, and existing heart disease. About 11,800 participants will take either vicadrostat or a p…

This study tests an oral drug called zongertinib in adults with advanced solid tumors that have HER2 mutations or overexpression and have not responded to prior therapy. Participants take one pill daily and are grouped by cancer type and HER2 alteration. The trial aims to see if …

This study tests an oral medicine called BI 1815368 for people with diabetic macular edema, a condition that causes vision loss due to fluid buildup in the eye. About 300 adults will take either the study drug or a placebo tablet twice daily for 11 months. The goal is to see if t…

This study tests a medicine called survodutide in 1590 adults with NASH or MASH cirrhosis, a serious liver condition. Participants receive weekly injections of survodutide or a placebo for up to 4.5 years, along with diet and exercise advice. The goal is to see if survodutide pre…

This early-phase study tests a new drug, BI 1703880, combined with ezabenlimab in adults with advanced solid tumors that haven't responded to other treatments. The main goal is to find the highest safe dose of BI 1703880. Participants receive both drugs as infusions, with BI 1703…

This study tests a daily pill called zongertinib for people with early-stage non-small cell lung cancer that has a specific HER2 gene change. After surgery to remove the cancer, participants either take zongertinib for up to 3 years or receive standard care (immunotherapy or obse…

This study tests a new drug, BI 3923948, in people with advanced solid tumors that have spread and are hard to treat. About 60 adults will receive the drug alone or with an immunotherapy (checkpoint inhibitor) to find the safest dose and see if it shrinks tumors. The drug is inje…

This study tests an experimental oral drug, BI 3000202, in 405 adults with moderate to severe systemic lupus erythematosus (SLE). Participants are randomly assigned to one of four doses of the drug or a placebo, taken daily for a year alongside their usual lupus treatments. The g…

This study looks at the long-term safety of a daily pill called nerandomilast for people with idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF). Participants must have completed a previous study with this drug. The goal is to see if the medicine is safe …

This study tests whether combining three different medicines can shrink tumors in adults with head and neck cancer that has spread or come back. Participants are split into three groups, each receiving a different mix of the drugs as infusions. The goal is to see if the combinati…

This study tests a new oral drug, zongertinib, that blocks HER2 — a protein that fuels cancer growth. It is for adults with advanced HER2+ breast, stomach, or colorectal cancer that has spread and no longer responds to standard treatments. The trial first finds the best dose of z…

This early-stage study tests a new drug called BI 3810944 in adults with advanced solid tumors or melanoma who have run out of treatment options. The main goals are to find safe doses and see if the drug can shrink tumors. Participants receive the drug every three weeks, with wee…

This early-stage study tests a new drug, BI 764532, in adults with advanced small cell lung cancer or other neuroendocrine cancers that have not responded to standard treatments. The drug is designed to help the immune system attack cancer cells. The main goal is to find the high…

This study tests whether the drug nerandomilast can slow or prevent lung scarring in people aged 40 and older who have early lung changes and a family history of pulmonary fibrosis. About 80 participants will take either the drug or a placebo twice daily for up to 3 years. Doctor…

This study looks at how different levels of liver problems (mild, moderate, severe) affect the way the body handles a single dose of the experimental drug BI 1584862. It includes 44 adults aged 18-80, both with and without liver issues, to compare results. Participants take the d…

This study checks whether two different versions of the drug survodutide (called Formulation A and Formulation B6) are absorbed and processed the same way in the body. It involves 80 healthy adults who are overweight or obese. Participants receive multiple doses of each version i…

This early-stage trial tests the safety and how the body handles a new drug called BI 3804379 in 106 healthy adults. Participants receive either the drug or a placebo as a single or repeated injection under the skin. The goal is to check for side effects and measure drug levels i…

This early-stage study is testing an experimental drug called BI 3031185 in healthy men aged 18 to 50. The main goal is to see if the drug is safe and how the body processes it. Participants will take multiple doses of the drug or a placebo. This study does not aim to treat any d…